- Home
- GIGM vs SLGL Comparison
GIGM vs SLGL Comparison
Compare GIGM & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- SLGL
- Stock Information
- Founded
- GIGM 1998
- SLGL 1997
- Country
- GIGM Taiwan
- SLGL Israel
- Employees
- GIGM N/A
- SLGL N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- SLGL Health Care
- Exchange
- GIGM Nasdaq
- SLGL Nasdaq
- Market Cap
- GIGM 16.1M
- SLGL 19.3M
- IPO Year
- GIGM 2000
- SLGL 2018
- Fundamental
- Price
- GIGM $1.43
- SLGL $8.02
- Analyst Decision
- GIGM
- SLGL Buy
- Analyst Count
- GIGM 0
- SLGL 1
- Target Price
- GIGM N/A
- SLGL $40.00
- AVG Volume (30 Days)
- GIGM 5.7K
- SLGL 6.4K
- Earning Date
- GIGM 07-30-2025
- SLGL 08-15-2025
- Dividend Yield
- GIGM N/A
- SLGL N/A
- EPS Growth
- GIGM N/A
- SLGL N/A
- EPS
- GIGM N/A
- SLGL N/A
- Revenue
- GIGM $3,103,000.00
- SLGL $12,103,000.00
- Revenue This Year
- GIGM N/A
- SLGL N/A
- Revenue Next Year
- GIGM N/A
- SLGL $31.17
- P/E Ratio
- GIGM N/A
- SLGL N/A
- Revenue Growth
- GIGM N/A
- SLGL 603.66
- 52 Week Low
- GIGM $1.27
- SLGL $3.34
- 52 Week High
- GIGM $1.80
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- GIGM 48.05
- SLGL 58.29
- Support Level
- GIGM $1.40
- SLGL $7.62
- Resistance Level
- GIGM $1.49
- SLGL $8.49
- Average True Range (ATR)
- GIGM 0.06
- SLGL 0.33
- MACD
- GIGM -0.00
- SLGL 0.08
- Stochastic Oscillator
- GIGM 28.12
- SLGL 61.88
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.